NCT03455244 is a clinical trial of FFRangio in Multi Vessel Coronary Artery Disease, sponsored by CathWorks Ltd..

Who is sponsoring NCT03455244?

NCT03455244 is sponsored by CathWorks Ltd..

What drugs are being tested in NCT03455244?

Interventions in NCT03455244: FFRangio.

What condition does NCT03455244 study?

NCT03455244 studies Multi Vessel Coronary Artery Disease.

Is NCT03455244 still recruiting?

NCT03455244 is currently completed. Last updated 25 June 2018.

Last reviewed 2018-06-25 · How we verify

NCT03455244

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Angiogram Based Fractional Flow Reserve in Patients With Multi-Vessel Disease

Completed Last updated 25 June 2018

What this trial tests

trial testing FFRangio in Multi Vessel Coronary Artery Disease in 50 participants. Completed in 2 May 2018.

Timeline

14 November 2017

Primary endpoint
2 May 2018

2 May 2018

Quick facts

Lead sponsor	CathWorks Ltd.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	14 November 2017
Primary completion	2 May 2018
Estimated completion	2 May 2018
Sites	1 location across Japan

Drugs / interventions tested

FFRangio

Conditions studied

Multi Vessel Coronary Artery Disease — all drugs for Multi Vessel Coronary Artery Disease →

Sponsor

CathWorks Ltd. — full company profile →

Who can join

18 and older, any sex, with Multi Vessel Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, observational, single-center, single-arm, clinical trial designed to assess the efficacy of FFRangio in measuring FFR obtained from angiography compared to Invasive FFR for diagnosing hemodynamically significant coronary stenosis in Multi-Vessel Disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of FFRangio

Trials testing the same drug.

NCT05648396 — Japan FFRangio Clinical Outcomes Study · active not recruiting
NCT03226262 — FFRangio Accuracy vs. Standard FFR · completed

Other recruiting trials for Multi Vessel Coronary Artery Disease

Currently open trials in the same condition.

NCT06104033 — Practice Change With Drug-coated Balloon in Patients With multiVessel Coronary Artery Disease · recruiting
NCT05527717 — Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogen · Phase 4 · recruiting
NCT05230446 — PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlus · NA · recruiting
NCT04968808 — Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI) · NA · recruiting
NCT03298659 — iFR Guided Multi-vessel Revascularization During Percutaneous Coronary Intervention for Acute Myocardial Infarction · NA · active not recruiting

Other CathWorks Ltd. trials

Trials by the same sponsor.

NCT03226262 — FFRangio Accuracy vs. Standard FFR · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03455244 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CathWorks Ltd.
Last refreshed: 25 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03455244.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing